Fidia Farmaceutici: revenues exceed €500 million in 2024
Fidia Farmaceutici: revenues exceed €500 million in 2024, up by more than 10% for the fifth consecutive year
- 2024 Turnover of €510.1 million (+10.1% y/y)
- Consolidated EBITDA of €97.5 million (+7.9% y/y)
- Growth in the Italian market of 10.9% y/y
- The United States (+14.6%), Europe (+13.6% y/y) and MENA countries (+13.7% y/y) are among the fastest-growing international geographical areas
- €29.3 million invested in R&D
- 5 patents registered in Italy and 94 internationally
Abano Terme , May 2025 – 2024 was a decisive year for Fidia Farmaceutici, a global leader in the research, development, production and marketing of innovative products mainly based on hyaluronic acid and its derivatives. The company continued its growth trajectory, achieving outstanding results and entering a new development phase.
Fidia ended the year with a turnover of €510.1 million (+10.1% compared to 2023), €503.3 million of which in revenues from product and service sales, an achievement made possible also thanks to a targeted acquisition plan driven by a long-term strategic vision. The consolidated EBITDA recorded an increase of + 7.9% compared to 2023, reaching €97.5 million.
The results once again confirm a strong growth trend at both a national and international level: between 2019-2024 Fidia recorded a steady growth in turnover, from €312 million in 2019 to €510 million in 2024, with a CAGR of 10.3%.
Investments in tangible and intangible assets amounted to approximately €210 million.
During the course of 2024, the most significant acquisition deal ever was finalised: Fidia acquired from Sanofi, a leading international pharmaceutical group, the manufacturing and marketing rights to a set of products specific to the area of gynaecology distributed in more than 34 countries with a strong focus on MENA countries (in particular Egypt, Turkey and Saudi Arabia), Asia (in particular the Philippines) and Europe. The strategy of geographic expansion and diversification of the core product portfolio, from which this transaction originates, is part of a path geared towards building a solid and sustainable growth model and allows Fidia to strengthen its development on the market, while reinforcing the company’s stability and its ability to face new competitive challenges.
Also in 2024, Fidia finalised the acquisition of 100% of Sanifarma, an Italian company active in the distribution of contact lenses, eye drops, dietary supplements and more. The company is active not only in the pharmacy channel but also in the mass retail and online channels and includes market-leading brands such as Contacta® and Correct®.
Simultaneously, a strategic commercial agreement was signed with the multinational Novartis, a leader in the development of innovative drugs, for the distribution, as early as in March 2024, of 6 ophthalmological medicinal products for the treatment of glaucoma, an eye disease that irreparably damages the optic nerve and induces a progressive reduction of the visual field to the point of causing, in the absence of treatment, complete blindness.
Geographical Areas
In a context that has seen a reduction in purchasing power for medicines paid in full by citizens and negative impacts on inventories in the distribution chain, Fidia has implemented strategies that have enabled it to record 11% higher growth than the market.
The Italian market accounted for 51.8% of the turnover (€260.4 million) and it marked an increase of +10.9% compared to 2023.
All major geographic regions recorded significant growth. The European market, in particular, grew significantly by +13.6 % (€120.4 million), while the MENA countries recorded +13.7% (€24.6 million). The United States grew by +14.6% (€62.3 million), fueled by the strong performance of Joint Care products and innovative solutionsin regenerative medicine.
Therapeutic Areas
Nearly all therapeutic areas achieved double-digit growth, with particularly strong results in Eye Care and Specialty Care, supported by the acquisition of new product portfolios and extraordinary corporate transactions.Regenerative medicine also delivered a solid performance, confirming its strong growth potential.
Research and Development
In 2024, Fidia registered 5 patents in Italy and 94 abroad (including ratifications of European patents), bringing its global patent portfolio to approximately 1446 patents, of which around 1231 related to the production, therapeutic use and pharmaceutical applications of hyaluronic acid.
During the year, €29.3 million was invested in research and development, with an increase of €3 million over the previous year (+12% y/y).
In the R&D area, the Group mainly focused its activities on the development of processes and technologies based on hyaluronic acid and its derivatives, as well as on their chemical-physical and biological characterisation, with a focus on core business areas (particularly joint care, skin care and aesthetic care).
Developments also continued in the Oncofid-P projects for the treatment of bladder cancer, the Collagenase project for the treatment of Dupuytren’s contracture and Peyronie’s disease, and other projects for the treatment of rheumatoid arthritis and osteoarthritis.
Human Resources
By year-end, the group’s workforce reached 1625 resources (1231 in Italy and 394 abroad), representing a 5% increase (154 resources in Italy and 134 in other countries).
In 2024, initiatives aimed at organisational change continued on a global level with a focus on corporate values and diversity, equity and inclusion, with the renewed confirmation of gender equality certification, the consolidation of the Group’s international vocation through the harmonisation of numerous processes and the implementation of awareness-raising and dissemination measures on DE&I issues.
“We are particularly proud to continue to pursue a path of solid and sustained growth, both domestically and internationally, despite a complex and uncertain macroeconomic environment” commented Carlo Pizzocaro, President and CEO of Fidia Farmaceutici. “These results are the outcome of a coherent strategy, a constant commitment to innovation and the team’s extraordinary ability to meet global challenges. This path, started by my father Francesco Pizzocaro in the 90s with vision and determination, continues today with the same commitment to excellence, strengthening the resilience and competitiveness of our Group and setting a clear direction towards the future.”